Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Daratumumab + Lenalidomide + Bortezomib + Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients Eligible for ASCT
KCT0006549Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2022; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0006549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006549.